药明生物发盈喜股价续涨近4%再破顶 康希诺续涨11% 君实AH急涨20%及曾涨逾8%
药明生物(02269.HK)发盈喜料中绩多赚逾58%,该股今早曾升破7月13日盘中所创上市高位158.9元,最高见162元,现造155.5元,续升3.7%。
与美国药厂辉瑞合作於中国推广产品及明日将就科创板上市进行网上路演的康希诺生物(06185.HK)承昨天重越10天线势,今天进一步升破20天线(223.85元),最高见251.4元,现造243.8元,续涨11%,成交增至4,909万股,涉资11.84亿元。此外,微创医疗(00853.HK)重越20天及10天线(39.4元),最高见41.15元,现造40.35元,回升4.5%。
君实生物(01877.HK)曾涨8.3%一举重越10天及50天线(49.4元及51元),最高见52元,现造50.2元,升4.6%;君实A股(688180.SH)急涨20%报126.6元人民币。
上海市新冠肺炎临床救治专家组组长兼公共卫生专家组共同组长张文宏教授近期接受《财约你》专访时表示,恢复期血浆和单克隆抗体是新冠特效药,已在开展临床研究,但产量有限。君实6月初曾宣布,与中国科学院微生物研究所共同开发重组全人源抗SARS-CoV-2单克隆抗体注射液已获国家药品监督管理局批准开展I期临床研究并已完成首例受试者给药。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.